Clinical Trial Update: Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule [Phase 2]

View source ↗

Summary

Phase 2 trial update on a booster dose of a tetravalent dengue vaccine in individuals who completed the 3-dose schedule; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever
• Dengue Hemorrhagic Fever

Drugs mentioned

• Tetravalent dengue vaccine

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Status: COMPLETED | Results posted: 2019-06-14